Commentary

Liquid Biopsy for Average-Risk Colorectal Cancer Screening

David A. Lieberman, Aasma Shaukat, Folasade P. May, John M. Carethers, Iris Lansdorp-Vogelaar, Uri Ladabaum, Timothy R. Church, Anjelica Davis, Chyke A. Doubeni, John M. Inadomi, et al.

ResearchPosted on rand.org Mar 28, 2024Published in: Clinical Gastroenterology and Hepatology (2024). DOI: 10.1016/j.cgh.2024.01.034

Despite well-known benefits and clear evidence of programmatic effectiveness in the average-risk population, colorectal cancer (CRC) screening in the United States remains underutilized. Only 60% to 65% of age-eligible individuals are up to date with screening. Emerging blood tests (liquid biopsies [LBs]) detecting circulating nucleotides such as cell-free DNA and/or metabolic products associated with CRC and its precursors could help expand screening. Introduction of new noninvasive screening tests could mitigate disparities, although the high cost could widen disparities.

Read More

Topics

Document Details

  • Copyright: AGA Institute
  • Publisher: Elsevier Inc
  • Availability: Non-RAND
  • Year: 2024
  • Pages: 12
  • Document Number: EP-70424

Research conducted by

This publication is part of the RAND external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.